Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.57 |
| ▸ | HTR1D | P28221 | 10/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7317348 | 0.99 | HTR1A (0.56) | HTR1AHTR1DCA2DRD2DRD4 | |
| SCHEMBL7321128 | 0.99 | HTR1A (0.56) | HTR1AHTR1DCA2DRD2DRD4 | |
| SCHEMBL7318326 | 0.99 | HTR1A (0.56) | HTR1AHTR1DCA2DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL7315820 | 0.97 | HTR1A (0.55) | HTR1AHTR1DCA2DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL7312318 | 0.97 | HTR1A (0.55) | HTR1AHTR1DCA2DRD2DRD4 | |
| SCHEMBL27471154 | 0.82 | HTR1A (0.60) | HTR1AHTR1DCA2 | |
| SCHEMBL7321831 | 0.81 | DRD2 (0.66) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL10850175 | 0.81 | CA2 (0.58) | HTR1AHTR1DCA2 | |
| SCHEMBL20138526 | 0.80 | CA2 (0.50) | HTR1AHTR1DCA2 | |
| SCHEMBL8864198 | 0.79 | DRD2 (0.72) | HTR1AHTR1DDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5318988-A | Treating psychoses | BAYER AKTIENGESELLSCHAFT (DE) | 1994-06-07 | — | — | US | claimed |
| US-5962513-A | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-05 | — | — | US | disclosed |
| EP-0540914-B1 | 2-Aminomethylchromans as active ingredients in medicaments for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1999-06-02 | — | — | EP | disclosed |
| US-5468882-A | Serotoninergic agents; central nervous system and psychological disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| US-5318988-A | Treating psychoses | BAYER AKTIENGESELLSCHAFT (DE) | 1994-06-07 | — | — | US | disclosed |
| EP-0540914-A1 | 2-Aminomethylchromans as active ingredients in medicaments for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1993-05-12 | — | — | EP | disclosed |